Modafinil

證據等級: L5

預測適應症: 1 個

Modafinil: From Narcolepsy to Insomnia

One-Sentence Summary

Modafinil is a wake-promoting agent used internationally for narcolepsy, shift work sleep disorder, and obstructive sleep apnoea, though it holds no CBG-MEB marketing authorisation in the Netherlands. The TxGNN model predicts it may be effective for Insomnia, with 29 clinical trials and 19 publications retrieved — however, the vast majority address excessive daytime sleepiness rather than insomnia directly. Critically, modafinil’s pro-wakefulness mechanism is pharmacologically opposite to the sedating action required for primary insomnia treatment, making this prediction plausible only in narrowly defined secondary-insomnia subgroups.

Quick Overview

Item	Content
Original Indication	Narcolepsy / Excessive Daytime Sleepiness (globally approved; no NL registration)
Predicted New Indication	Insomnia
TxGNN Prediction Score	99.85%
Evidence Level	L3
NL Market Status	Not registered (no CBG-MEB authorisation)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Modafinil is a wake-promoting agent whose mechanism centres on inhibiting the dopamine transporter (DAT), enhancing histaminergic H1 signalling, and activating the hypothalamic orexin (hypocretin) pathway — together sustaining wakefulness and reducing excessive daytime sleepiness. It is approved in multiple jurisdictions (FDA, EMA) for narcolepsy, residual sleepiness in obstructive sleep apnoea, and shift work sleep disorder. Detailed MOA data was not included in this Evidence Pack; the above is drawn from published evidence-based reviews (PMID 18729534). Currently, detailed mechanism of action data is not available in the regulatory record for the Netherlands. Based on known pharmacological information, modafinil is a wake-promoting stimulant whose efficacy for excessive daytime sleepiness has been firmly established across multiple approved indications.

There is a fundamental mechanistic paradox in this prediction. Primary insomnia — characterised by difficulty initiating or maintaining sleep — requires a sedating or sleep-promoting intervention, which is the pharmacological opposite of modafinil’s action. The high TxGNN score (99.85%) most likely reflects the model’s recognition of broad graph-level adjacency between modafinil and the generic “sleep disorder” disease node, rather than an insomnia-specific therapeutic signal. This distinction is clinically important.

However, a limited mechanistic rationale does exist for secondary insomnia: in patients where excessive daytime sleepiness leads to compensatory napping and disrupts the homeostatic sleep drive, modafinil could theoretically normalise daytime wakefulness, consolidate the circadian sleep–wake rhythm, and thereby indirectly improve nocturnal sleep quality. Clinical evidence supports this hypothesis in narrow populations — cancer survivors with chemotherapy-related fatigue and co-occurring insomnia, and patients with neurodegenerative disease whose fragmented sleep is driven by circadian dysregulation. This is a context-specific repurposing hypothesis and does not support broad application of modafinil for primary insomnia.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00124384	Phase 4	Completed	40	The only registered trial targeting primary insomnia directly with modafinil; examines modafinil alone or in combination with CBT-I to improve daytime functioning and reduce insomnia severity
NCT01019187	Phase 2	Completed	226	Randomised trial of CBT-I ± armodafinil (R-enantiomer of modafinil) for cancer survivor insomnia and fatigue post-chemotherapy; armodafinil serves as a pharmacological proxy for modafinil
NCT01091974	Phase 2	Completed	138	Four-arm RCT of CBT-I and armodafinil in female breast cancer patients with post-chemotherapy sleep disturbances; provides the most rigorous direct armodafinil-insomnia dataset
NCT01011218	Phase 2	Completed	70	Pilot RCT in breast cancer patients; armodafinil 150 mg/day combined with brief or standard CBT-I to manage cancer-related insomnia
NCT02552303	N/A	Completed	39	Armodafinil, CBT-I, or combination for insomnia comorbid with obstructive sleep apnoea; measures sleep continuity and CPAP adherence
NCT06404086	Phase 2	Completed	830	RECOVER-SLEEP platform trial: evaluates multiple interventions for sleep disturbances in long COVID (PASC); flexible platform design allowing comparative analysis across intervention arms
NCT06404099	Phase 2	Active (not recruiting)	361	Second RECOVER-SLEEP platform arm: ongoing evaluation of sleep interventions in post-acute COVID sequelae
NCT01965925	Phase 4	Completed	18	8-week, randomised, placebo-controlled trial of modafinil in stable bipolar disorder, targeting both sleep-wake cycle disruption and residual cognitive impairment
NCT07295834	Phase 2	Not yet recruiting	70	Double-blind RCT of modafinil vs. placebo (12 weeks) for severe fatigue in inflammatory bowel disease; the only forthcoming direct modafinil trial; not yet started
NCT00626210	Phase 4	Terminated	2	Modafinil for sleep/wake disturbances in older adults; terminated after only 2 participants enrolled — no meaningful conclusions can be drawn

Literature Evidence

PMID	Year	Type	Journal	Key Findings
18219235	2008	Randomised Trial	J Head Trauma Rehabil	Modafinil reduced fatigue and excessive daytime sleepiness in chronic traumatic brain injury; illustrates that wakefulness normalisation may indirectly benefit fragmented sleep architecture
18729534	2008	Evidence-Based Review	Drugs	Comprehensive review of modafinil’s approved and investigational uses across double-blind RCTs; confirms wake-promoting MOA and approved evidence base; no direct insomnia indication found
24312590	2013	Meta-Analysis	PLoS One	Meta-analysis of modafinil for fatigue and EDS in neurological disorders; results inconsistent across conditions; no demonstrated direct improvement of nocturnal sleep
22021174	2011	Systematic Review / EBM	Movement Disorders	MDS evidence-based review of Parkinson’s non-motor symptom treatments including sleep; modafinil recommended for EDS but evidence base for insomnia in PD remains insufficient
27010071	2016	Systematic Review	Parkinsonism Relat Disord	Systematic review of pharmacological interventions for daytime sleepiness in Parkinson’s; highlights that few high-quality trials address insomnia specifically
39535843	2024	Narrative Review	Expert Opin Pharmacother	Most current review of sleep dysfunction in Parkinson’s; notes modafinil role in managing EDS but underlines that nocturnal insomnia management in PD remains an unmet need
20082966	2009	Review	Parkinsonism Relat Disord	Describes narcolepsy-like napping in Parkinson’s disease; modafinil addresses daytime symptoms but has not been shown to improve nighttime sleep in this population
18805301	2008	Review	Rev Neurol	Review of narcolepsy with cataplexy; notes sleep maintenance insomnia as a co-occurring feature of narcolepsy and discusses modafinil’s primary role in daytime symptom control
30214155	2018	Review	Drug Des Dev Ther	Profiles pitolisant as a newer narcolepsy treatment; provides comparative context for modafinil’s mechanism and its limitations in addressing nocturnal sleep disruption
17060310	2006	Case Series	Am J Hosp Palliat Care	Modafinil reduced fatigue in Charcot-Marie-Tooth disease type 1A; illustrates off-label use pattern in fatigue-predominant conditions with secondary sleep disruption

Netherlands Market Information

Modafinil currently holds no CBG-MEB marketing authorisation in the Netherlands and does not appear in the Dutch national medicines register. Any prescribing in the Netherlands would require an individual import authorisation, a named-patient supply arrangement, or an off-label use pathway, each requiring explicit clinical justification and pharmacovigilance planning.

RVG Number	Product Name	Dosage Form	Approved Indication
—	No registered products	—	—

Safety Considerations

Please refer to the SmPC (Summary of Product Characteristics / Samenvatting van de Productkenmerken) for safety information.

Given the absence of a CBG-MEB authorisation and the lack of safety data in this Evidence Pack, the EMA SmPC for the EU-registered modafinil product (where applicable) and published pharmacovigilance literature should be reviewed before any clinical decision. Key areas to examine include hypersensitivity reactions, CYP enzyme interactions, cardiovascular precautions, and potential for dependence or misuse.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction score of 99.85% for modafinil in insomnia most likely reflects broad graph-level adjacency to the “sleep disorder” disease cluster rather than a genuine insomnia-specific therapeutic signal. Modafinil’s pro-wakefulness mechanism is pharmacologically opposed to primary insomnia treatment; the only evidence of mechanistic plausibility is in secondary insomnia driven by circadian disruption (e.g., cancer-related fatigue, neurodegenerative disease). Direct clinical evidence is limited to one small completed Phase 4 trial (NCT00124384, n=40) plus several armodafinil studies in oncology populations. Modafinil is unregistered in the Netherlands, and critical safety and MOA data gaps remain unresolved.

To proceed, the following is needed:

Indication scoping: Determine whether the clinical target is primary insomnia or a specific secondary-insomnia subgroup (e.g., post-chemotherapy, neurodegeneration-related); these require different evidence packages and regulatory strategies
Safety documentation: Obtain the current EMA/nationally authorised SmPC for modafinil to complete the S1 safety assessment — in particular contraindications, warnings, and DDI profile (CYP3A4 interactions are clinically significant)
MOA confirmation: Retrieve DrugBank DB00745 MOA data to formally document mechanism and support or refute the mechanistic hypothesis for the target indication
Regulatory landscape check: Confirm whether EMA or any EU national competent authority has previously reviewed modafinil for an insomnia indication; check for any EPAR entry or prior scientific advice
Subgroup literature review: If pursuing secondary insomnia, commission a focused systematic review in the cancer-survivor and circadian-disruption populations, where the circadian-restoration hypothesis is most mechanistically grounded
CBG-MEB pre-submission consultation: Given zero NL authorisations, early dialogue with CBG-MEB is advisable before initiating any formal development programme in the Netherlands
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.